PROCEPT BioRobotics Aktie News

PROCEPT BioRobotics Corporation ( PRCT ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Matthew Bacso - Vice President of Investor Relations Larry Wood - President, CEO & Director Kevin Waters - Executive VP & CFO Conference Call Participants Matthew O'Brien - Piper Sandler & Co., Research Division Brandon Vazquez - William Blair & Company L.L.C., Research Division Rich...

SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2025.

Robotics companies building enabling systems like sensors and LiDAR attracted $1.6 billion in 2025, as every robot needs vision capabilities. Medical robotics shows the clearest path from startup to profitability, with surgical automation growing 56% annually in emerging procedures.

Chicago Capital added 999,873 shares of Procept BioRobotics with an estimated purchase value of $45.65 million based on the average price for the quarter. The transaction represents a trade size equal to 1.12% of Chicago Capital's 13F reportable assets under management (AUM) for the period.

SAN JOSE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2025 after market close on Tuesday, November 4, 2025. The Company's management will host a co...

PROCEPT BioRobotics stands out in BPH therapy with its unique Aquablation technology and razor-and-blade business model, driving strong, recurring growth. PRCT's robust R&D investment, expanding indications, and international momentum support margin expansion, scalability, and long-term growth in its niche market. Valuation is attractive at current levels, with a DCF-derived target price of $50...

It is tempting to believe the next Nvidia (NASDAQ:NVDA ) or Palantir (NASDAQ:PLTR ) is hiding in plain sight and will quickly give you multibagger returns.

Procept BioRobotics Corporation is in the early stages of penetrating a massive $20B BPH surgery market with its innovative, recurring-revenue robotic systems. The company's strong revenue and install base growth, favorable reimbursement, and increasing ASPs support my buy rating and $44 fair value estimate. Gross margin expansion is expected from pricing power, scale, and cost control, with br...